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The human immunodeficiency virus (HIV) has a marked tropism for human T
lymphocytes expressing the CD4 glycoprotein. This molecule has been identified
as the major cellular receptor for the HIV envelope protein gp120 (reviewed in refer-
ence 1). However, several othercells, such as dendritic cells, glialcells, monocytes/mac-
rophages, and myeloid progenitor cells, which all express low levels of the CD4 mol-
ecule, can also be infected by HIV (2-5). Recent reports have suggested that the
CD4 molecule may not be the only binding site permitting virusentry. In fact, HIV
infection of brain and muscle cells could not be prevented by soluble CD4 or mAbs
against CD4 (6). Infection of CD4- human fibroblastoid cells has also been demon-
strated (7).
A large proportion of sera from HIVinfected subjects have been shown to en-
hance HIV infection in vitro via an antibody-dependent enhancement (ADE) mech-
anism; this suggests that both Fc and complement receptor (CR) might be involved
in the internalization of HIV! in some cases. Fc receptor enhancement of HIV in-
fectivity has been reported in several cell types (8, 9); however, there is only one
report describing a role for CR in enhancement of HIV infectivity in a T cell line
expressing unusually high levels of CD4 and CR2 (10). With the knowledge that
EBVtransformed B cells are often CD4+ and express high levels of CR2, which is
the receptor for EBV, we have studied the involvement ofthis latter molecule in the
enhancement ofHIV infectivity. Our results demonstrate a very significant enhance-
ment of HIV-1 infection in these cells by a mechanism involving CR2. Furthermore,
the enhancement is strictly dependent on the expression of CD4.
Materials and Methods
BriefDefinitive Report
Establishment ofEBV-carrying B CellLinesandSera.
￿
PBMC, isolated from each oftwo healthy
donors,were infected with theB95-8strain of EBV, as previously described(11). Serumsamples
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were obtained from three HIV-1-infected individuals. Two of these patients were asymptom-
atic and one fulfilled the criteria for AIDS ofthe Centers for Disease Control (12). Additional
sera from healthy sero-negative donors were used as controls. Sera were heat inactivated (HI)
for30 min at 56°C before use. Lyophilized humancomplement-containing serum from Sigma
Chemical Co. (St. Louis, MO) was used as a source of human complement and was recon-
stituted immediately before use.
Viruses.
￿
The HIVIIIR strain of HIV-1 was harvested from culture fluids of the chroni-
cally infected H-9 T lymphoid cell line, kindly supplied by Dr. R. C. Gallo (National Insti-
tutes of Health, Bethesda, MD) (13). A clinical variant of HIV1, recently isolated in our
laboratory by a coculture assay (14), was also included in the study. Titers of these HIV-1
preparations were determined by plaque assay using MT-4 cells (HTLVI-carrying cells) as
targets (15).
Immuno,fluorescence and Progeny Virus Production.
￿
The presence of HIV-1 antigens was de-
tected by an indirect immunofluorescence assay. Toward this end, mouse mAbs specific for
the viral core protein p24 (kindly supplied by Dr. R. C. Gallo) were used in conjunction
with a FITC-conjugated goat anti-mouse Ig (Cappel Laboratories, Cochranville, PA). Infec-
tious titers (TCID50) of progeny virus production in culture supernatant fluids were calcu-
lated using the Karber formula, on the basis of viral cytopathicity for MT-4 cells.
Flow Cytometry.
￿
Mouse mAbs used in these studies were anti-Leu-3a (anti-CD4) (Becton
Dickinson Immunocytometry Systems, Mountain View, CA) and OKB7 (anti-CR2)(Ortho
Diagnostics Systems Inc., Westwood, MA). EBVpositive B cells were first incubated with
the appropriate mAb, washed, and incubated with FITC-conjugated goat anti-mouse Ig.
The fluorescence data of 10,000 cells were analyzed using a FACScan flow cytometer (Becton
Dickinson Immunocytometry Systems). Nonspecific stainingwas determinedusing nonbinding
isotype-matched mAbs.
Complement-mediated ADE of HIV-1 Infection.
￿
200,ul of culture fluid containing HIV-1 (105
TCID5o for HIVIIIR, and 10° TCID5o for the clinical isolate) was mixed with an equal
volume of HI HIV-1 antibody-positive serum, supplemented with 1 :20 human comple-
ment-containingserum, and incubated for 1 h at 37°C. Then, 5 x 105 EBVcarrying B cells
were added to each sample and incubated for 2 h at 37°C. The cells were washed twice and
resuspended in 500 11 offresh medium before seeding. Samples were harvested periodically
and assayed for viralinfection. Controls were performed using sera from HIV-1 antibody-nega-
tive individuals.
Results and Discussion
The role of complement-mediated antibody-dependent enhancement (CM-ADE)
ofHIV infection was studied in two independently derived EBVcarrying B cell lines.
These two cell lines (A and B) expressed variable levels of both CR2 (Fig. 1, A and
C) and CD4 (Fig. 1, B and D), as shown by flow cytometry histograms. Although
these two cell lines also expressed Fc receptors, we could not detect any ADE ofHIV-1
infectivity using sera from each of three seropositive individuals (Fig. 2).
The two B cell lines were infected with HIVIIIB in the presence of the above-
mentioned HIV-1-positive sera and a constant amount ofhuman complement (1 :20).
The results of Fig. 2 A indicate that a significant increase (2-5-fold) in the number
of cells expressing HIV-1 p24 antigen was observed in cell line A, after 8 d of ex-
posure to the virus. Cell line B, which expressed low levels of CR2 and CD4, was
almost nonsusceptible to HIV-1 infection (Fig. 2 B). However, when these cells were
incubated with HIVIII$, together with the above-mentioned sera and complement,
a 5-10-fold increase in the percentage of cells that expressed p24 was observed.
To confirm that this phenomenon was not restricted to HIV-114, the same ex-
periments were performed on cell line A with a clinical isolate of HIV-1. As shown
in Fig. 2 C, a similar enhancement effect was observed in the CM-ADE assay.W
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FIGURE 2 .
￿
Complement-mediated ADE of HIV1 infection in EBVtransformed B cell lines.
(A-C) EBVpositive B cell lines were infected with HIV-1 alone ([3), HIV-1 plus human comple-
ment (N), or HIV-1 plus a 10 -4 dilution of serum 1, 2, and 3 in the absence (0) or presence
(®) of human complement (1 :20) . Samples were harvested at regular intervals and assayed for
p24 antigen by indirect immunofluorescence . (A) Percentage ofp24-positive cells 8 d after infec-
tion of cell line A with HIVIIIK . (B) Percentage of p24-positive cells 12 d after infection of cell
line B with HIV-IIIR . (C) Percentage of p24-positive cells 12 d after infection of cell line A with
a clinical isolate ofHIV 1 . (D) Results obtained with EBVpositive B cell lineA was infected with
HIV-1 alone (Q), HIV-1 plus human complement (N), HIV-1 plus cobra venom factor (0),
or HIV-1 plus a 10-4 dilution of serum 1, 2, and 3 supplemented with human complement (1 :20)
and pretreated in the absence (EI) or presence (®) of cobra venom factor. The percentage of
p24-positive cells at 8 d after infection is shown . The data are the means ± SEM of determina-
tions carried out with three replicate samples.
FIGURE 1 .
￿
Flow cytometry analysis oftwoEBV
transformed B cell lines, showing surface expres-
sion ofCR2 andCD4 . EBVpositive cell linesA
(A and B) and B (C and D) were first incubated
with the murine mAbsOKB7 (A and C, solid lines)
and anti-Leu-3a (B and D, solid lines), washed,
and subsequently exposed to FITC-conjugated
goat anti-mouse Ig . The fluorescence ofthesecells
was analyzed using a FACScan flow cytometry .
The dashed line represents background fluores-
cence . M.F.V ., mean fluorescence value.
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We also investigated whether the CM-ADE of HIV -1 infection would result in
increasedprogeny virus production . Table I shows that theyields ofinfectious virus
in culture supernatants were increased by 3-10-fold when cells were infected in the
presence of any of three samples of HIV-1-positive sera and human complement.
It has been reported that HIV-1-infected EBVpositive B cells can be isolated from
thePBMC ofpatients with AIDS-related complex (ARC) andAIDS (16) . Ourresults
support the notion that EBVtransformed B cells, which are noteworthy for their
high expression of CR2 and which can also express CD4, may participate in the
pathogenesis ofdisease by releasingmore infectious viral particles after HIV-1 infec-
tion through the CM-ADE mechanism.
Experiments were performed to determine what the effect ofcomplement deple-
tionwould be on the observed CM-ADE ofHIV-1 infection. Fig. 2D indicates that
cobra venom factor, which is known to cause the inactivation of C3, inhibited the
CM-ADE of HIV-1 infection when included in the assay.
We next carried out a series of experiments to identify the molecules involved in
theCM-ADE ofHIV -1 infection . The involvement ofCD4 in theCM-ADE mecha-
nism was clearly demonstrated by the observation that anti-Leu-3a, amAb specific
forthe gp120 binding site ofCD4, totally abrogated HIV-1 infection in the presence
of HIV-1-positive sera and complement (Fig . 3 A) . This inhibition occurred at con-
centrations as low as 25 ng/ml, confirming that CD4 is the primary binding site
forHIV1 . Fig. 3B shows that mAb OKB7, which is specific forthe CR2, inhibited
the increase in p24-positive cells in a dose-dependent fashion . Complete inhibition
of the CM-ADE was observed when 10 /kg/ml ofOKB7 was used . Control experi-
ments were performed using D1-12, amAb specific toMHC class II molecules . This
mAb did not inhibit HIV-1 infection .
These results indicate that CD4 and CR2 synergize for the entry of HIVI into
EBVtransformed B cells . This'synergy might be relatively important in cells that
expresslow levels ofCD4and/or wherethefusion-mediated entry of HIV-1 is inefficient
(e.g ., cell line B) . In our model, the CR2 structure would permit HIV-1 infection
through viral endocytosis after initial binding to CD4. It is relevant that CR2 has
previously been reported to mediate the internalization of EBV via an endocytic
pathway (17) .
TABLE I
Presence of Progeny Virus in Cellfree Culture fluids of HIV-1-infected Cells
Titers of infectious virus were determined in culture fluids 8 d after HIV-1
infection (HIV-III B ) of an EBV-transformed B cell line (cell line A) in the
presence of sera from HIV-1-infected subjects and human complement, as
described in Materials and Methods .
" HIV-1 alone .
HIV-1 +
serum dilution 1
Serum sample
2 3
TCIDSo x 105/ml
0" 8.95 t 1 .7 5.04 t 1 .2 8.95 t 1 .8
10-3 28.32 t 3 .4 50.36 t 4 .5 28.31 t 2 .8
10-4 15.92 t 2 .1 28.31 t 1 .9 15.92 t 2 .4N
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FIGURE 3.
￿
CR2 and CD4 are required for complement-mediated ADE of HIV-1 infection in
EBVcarrying B cells lines. EBVpositive B cells (cell line B) were incubated for 2 h at 37°C with
varying dilutions ofanti-Leu-3A (A) or OKB7 (B) ([3). These cells were then washed, and in-
fected with HIVIII,I in the presence of 10-4 dilution of serum 1, supplemented with human com-
plement (1 :20). Controls consisted of EBVcarrying B cells, nontreated with the above mentioned
mAbs, infected with HIVIIIB alone ((]), or HIV-1 plus a 10-4 dilution of serum 1 in the pres-
ence of human complement (1 :20) (/). The data represent the percentage of p24-positive cells
12 d after viral infection.
The phenomenon of CM-ADE of HIV-1 infection observed in EBVcarrying B
cells thus involveseach the CD4 receptor, theCR2, and complement. This enhance-
ment of HIV-1 infection was detected using sera from each of two asymptomatic
individuals and one patient with AIDS. Ourresults suggest that HIV-1 may be able
tomore efficiently infect EBVcarryingB cells in vivo througha CD4-CR2 receptor
complex. This may allowforcircumvention ofthe effects ofneutralizing antibodies.
It is further relevant that, in contrast to normal B cells, most EBVtransformed
Bcell lines expresscell surface CD4tosomedegree (18). Indeed, theabilityofHIV-1
to infect such cells can be blocked by anti-CD4 antibodies, regardless ofthe extent
ofcell surfaceCD4 representation. This issue mayhave importantclinical relevance,
given that the numbers of EBVtransformed B cells are elevated in patients with
AIDS and, accordingly, could represent an important target for HIV-1 in such indi-
viduals (18). Moreover, EBVcarryingB cells are relatively resistant to the cytopathic
effects of HIV1, in comparison with T lymphocytes (18).
Summary
Although the CD4 glycoprotein is the primary receptor forHIV-1, recent reports
have suggested thatothermolecules might beinvolved in the enhancement ofHIV-1
infection. Weinvestigated the possible roleofthe complement receptor 2 inenhance-
ment ofHIV-1 infection in CD4+ EBVcontaining B cells by infecting such cells in
the presence ofsera from HIV sero-positive donors, with or without added human
complement. A marked increase in production ofviral p24 and infectious progeny
virus wasobservedonlywheninfectionhadbeen carriedoutinthepresence ofhuman
complement. The addition ofmAb tothe human complement receptor 2 completely
inhibited this enhancement. This mechanism was CD4 dependent, suggesting a
cooperative effect between these two ligands in the potentiation of viral entry.1796
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